Key regions: Brazil, India, Australia, United States, United Kingdom
The Antiviral Drugs market in Central & Western Europe has been showing steady growth in recent years.
Customer preferences: Customers in Central & Western Europe are increasingly aware of the importance of preventing and treating viral infections. This is due to the high prevalence of viral diseases in the region, such as influenza and hepatitis. As a result, there is a growing demand for antiviral drugs that can effectively treat and prevent these diseases.
Trends in the market: One of the major trends in the Antiviral Drugs market in Central & Western Europe is the increasing use of combination therapies. Combination therapies involve using two or more antiviral drugs to treat a viral infection. This approach has been shown to be more effective than using a single drug, as it can help prevent the development of drug-resistant strains of the virus.Another trend in the market is the development of new antiviral drugs. Pharmaceutical companies are investing heavily in research and development to create new drugs that are more effective and have fewer side effects than existing drugs. This is driving innovation in the market and providing new treatment options for patients.
Local special circumstances: Central & Western Europe is home to a number of leading pharmaceutical companies that are active in the Antiviral Drugs market. This has led to a highly competitive market, with companies competing to develop and market the most effective drugs. Additionally, the region has a well-developed healthcare infrastructure, which has helped to drive demand for antiviral drugs.
Underlying macroeconomic factors: The Antiviral Drugs market in Central & Western Europe is being driven by a number of macroeconomic factors. These include increasing healthcare spending, an aging population, and the high prevalence of viral diseases in the region. Additionally, the region has a highly educated population that is increasingly aware of the importance of preventative healthcare, which is driving demand for antiviral drugs.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
